illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. NuVasive
Company logo

NuVasive | Sustainability Performance

https://www.nuvasive.com
Linkedin

Develops medical devices and procedures, particularly focusing on solutions for spinal surgery and related healthcare applications.

1997

United States

1,001 - 5,000 employees

Medical Device

$1B - 10B in revenue

$25M - 100M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#5704
Overall
#1186
in United States
#85
in Medical Device

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies

Company logo
Arcturus Therapeutics

United States, Hospital & Health Care, Biotechnology

Company logo
NeueHealth

United States, Hospital & Health Care, Hospital & Health Care

Company logo
Envista

United States, Hospital & Health Care, Medical Device

Market cap

2.3B $, 2023▼16.2% YoY

Revenue

1.2B $, 2022▲5.3% YoY

R&D intensity

8.16% 2022

Controversy level

Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • NuVasive Inc, US spine medical devices, has faced multiple US FDA Form 483 observations at multiple production facilities, plus the contested 2023 Globus Medical USD 3.1 billion acquisition antitrust review and the historic 2021 USD 3.5 million SEC settlement over alleged inadequate revenue recognition disclosure during 2018-2020 reporting.
Powered by illuminem

Market cap

2.3B $, 2023▼16.2% YoY

Revenue

1.2B $, FY2022▲5.3% YoY

EBITDA

113.0M $, FY2022▼9.1% YoY

Operating margin

5% Industry: -136▲48.9% YoY

Revenue & EBITDA

$1.2BFY2022 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Revenue by region

Revenue by region %

Non-US [Member]
UNITED STATES [Member]

Powered by illuminem

Margin trends

Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

29.7M 2022▼134.8% YoY

Capex

139.0M 2022▲19.4% YoY

Debt/equity ratio

1.0 Industry: 1▼NaN% YoY

R&D intensity

8.2%FY2022

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

2.0%FY2026
Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals

Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

1.1

▼ 0.1%

2020

1.1

▲ 0.2%

2021

1.2

▼ 0.6%

2022

1.7

2027

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Available

Recycling policy

Not available

Workplace health & safety policy

Available

57%
Independent Directors

8 out of 14 incl. management

Powered by illuminem

Overall score

40

Environment

2

Social

89

Governance

30

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

 Available

Sustainability employees

Total sustainability employees

2-3

    Available in
    Scale package

    Access
  • Email
  • Email